GKOS GLAUKOS Corp
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1192448 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY46.9%
TTM net income YoY-93.8%
TTM EPS YoY-91.6%
Revenue 3-yr CAGR31.5%
Net income 3-yr CAGR—
Margins
Gross margin64.8%
Operating margin-25.5%
Net margin-24.6%
FCF margin5.2%
EBITDA margin-19.5%
Returns
ROE-22.8%
ROA-17.2%
ROIC (approx.)-22.8%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets26.8%
Debt / equity0.00x
Current ratio4.57x
Interest coverage-36.57x
Cash quality & payout
Operating cash flow / net income-0.28x
Accruals ratio-22.0%
Payout ratio—
Capex / revenue1.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $507.44M | $383.48M |
| Cost of revenue | $111.81M | $94.03M |
| Gross profit | $282.76M | $289.45M |
| R&D expense | $150.61M | $136.43M |
| SG&A expense | $331.75M | $261.17M |
| Operating income | -$199.60M | -$122.37M |
| Interest expense | $4.63M | $10.04M |
| Pretax income | -$193.04M | -$145.60M |
| Income tax | -$5.35M | $771,000 |
| Net income | -$187.69M | -$146.37M |
| EBITDA | -$161.51M | -$86.72M |
| EPS (basic) | -3.28 | -2.77 |
| EPS (diluted) | -3.28 | -2.77 |
| Weighted avg. shares (diluted) | 57.19M | 52.76M |
| Balance sheet | ||
| Cash & equivalents | $90.81M | $174.36M |
| Receivables | $108.61M | $60.74M |
| Inventory | $63.56M | $57.68M |
| Current assets | $474.98M | $449.79M |
| PP&E, net | $113.25M | $97.87M |
| Goodwill | $66.71M | $66.13M |
| Intangibles | $141.92M | $263.44M |
| Total assets | $893.49M | $974.76M |
| Current liabilities | $101.28M | $75.12M |
| Total liabilities | $237.33M | $207.82M |
| Shareholders' equity | $656.15M | $766.93M |
| Shares outstanding | 57.51M | 56.44M |
| Cash flow statement | ||
| Operating cash flow | -$14.79M | -$61.32M |
| Capital expenditure | $7.67M | $6.30M |
| Free cash flow | -$22.45M | -$67.62M |
| Investing cash flow | -$77.61M | $47.83M |
| Financing cash flow | $11.89M | $91.54M |
| Depreciation & amortization | $38.09M | $35.65M |
| Stock-based compensation | $63.22M | $50.21M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.